May 12, 2020 - Publication of a driving study demonstrating the effects of tolperisone

February 26. 2020 - Neurana Pharmaceuticals to participate in Cowen Health Care Conference

November 7, 2019 - Randall Kaye, M.D., appointed as Chief Medical Officer

October 14, 2019 - Neurana Pharmaceuticals to participate in Solebury Trout Private Company Showcase

September 23, 2019 - Positive topline results from Phase 2 STAR Study of tolperisone in acute muscle spasms of the back

June 17, 2019 - Completed enrollment in Phase 2 STAR Study of tolperisone in over 400 patients

October 17, 2018 - Presentation will highlight data demonstrating the non-sedating effects of tolperisone

October 17, 2018 - Presentation will highlight data demonstrating the non-sedating effects of tolperisone

July 17, 2018 - Craig brings over 25 years of executive, commercial and marketing experience to Neurana

May 7, 2018 - Funding to advance tolperisone led by Sofinnova Ventures

February 4, 2019 - First patient enrolled in Phase 2 dose ranging study of tolperisone

October 26, 2017 - Non-sedative effects of tolperisone confirmed in Phase 1 study

October 26, 2017 - Study to assess non-sedating properties of tolperisone initiated

May 25, 2017 - Notice of Allowance patents received for two, new tolperisone patents